Skip to main content
Erschienen in: Pathology & Oncology Research 2/2012

01.04.2012 | Research

Clinical and Biological Significance of Never in Mitosis Gene A-Related Kinase 6 (NEK6) Expression in Hepatic Cell Cancer

verfasst von: Xiaolei Cao, Yunfei Xia, Junling Yang, Jinxia Jiang, Li Chen, Runzhou Ni, Liren Li, Zhifeng Gu

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Nek6 is a cell cycle regulatory gene, which can control cell proliferation and survival. Recent studies suggested that desregulation of Nek6 expression plays a key role in oncogenesis. This study was aimed to investigate the potential roles of Nek6 in hepatocellular carcinoma (HCC) development. Immunohistochemistry and Western blot analysis was performed for Nek6 in 80 hepatocellular carcinoma samples. The data were correlated with clinicopathological features. The univariate and multivariate survival analyses were performed to determine the prognostic significance of Nek6 in HCC. In addition, Nek6 expression vector was used to detect its role in cell cycle control. Nek6 was overexpressed in hepatocellular carcinoma as compared with the adjacent normal tissue. High expression of Nek6 was associated with histological grade and the level of alpha fetal protein, and Nek6 was positively correlated with proliferation marker Ki-67. Univariate analysis showed that Nek6 expression was associated with poor prognosis. Multivariate analysis indicated that Nek6 and Ki-67 protein expression was an independent prognostic marker for HCC. While in vitro, following release from serum starvation of HuH7 HCC cell, the expression of Nek6 was upregulated. Overexpression Nek6 in Huh7 cell could promote the cell cycle. In conclusion, Nek6 is involved in the pathogenesis of hepatocellular carcinoma. It may be a favorable independent poor prognostic parameter for hepatocellular carcinoma.
Literatur
1.
2.
Zurück zum Zitat Di Bisceglie AM (2004) Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 127:S104–S107PubMedCrossRef Di Bisceglie AM (2004) Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 127:S104–S107PubMedCrossRef
3.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 94:153–156PubMedCrossRef Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 94:153–156PubMedCrossRef
4.
Zurück zum Zitat Curado MP, Edwards B, Shin HR et al (2007) Cancer incidence in five continents (IARC, Lyon, France) IARC Scientific Publications, No. 160, Vol. IX Curado MP, Edwards B, Shin HR et al (2007) Cancer incidence in five continents (IARC, Lyon, France) IARC Scientific Publications, No. 160, Vol. IX
5.
Zurück zum Zitat Sean FA, Katherine AM, Marsha ER (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. JCO 27(9):1485–1491CrossRef Sean FA, Katherine AM, Marsha ER (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. JCO 27(9):1485–1491CrossRef
6.
Zurück zum Zitat Bosch FX, Ribes J, Diaz M, Cleries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5):S6–S16CrossRef Bosch FX, Ribes J, Diaz M, Cleries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5):S6–S16CrossRef
7.
Zurück zum Zitat Lai PBS, Tianyi C, George GC (2007) Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro. Apoptosis 12(2):387–393PubMedCrossRef Lai PBS, Tianyi C, George GC (2007) Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro. Apoptosis 12(2):387–393PubMedCrossRef
8.
Zurück zum Zitat Siddhartha K, Meifang W, Brian IC (2008) 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis. Cancer Chemother Pharmacol 62(5):831–840CrossRef Siddhartha K, Meifang W, Brian IC (2008) 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis. Cancer Chemother Pharmacol 62(5):831–840CrossRef
9.
Zurück zum Zitat Wang H, Pan K, Zhang H et al (2008) Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 134(5):535–541PubMedCrossRef Wang H, Pan K, Zhang H et al (2008) Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 134(5):535–541PubMedCrossRef
10.
Zurück zum Zitat Laura G, Manuela F, Francesca F et al (2007) Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 67(13):6092–6099CrossRef Laura G, Manuela F, Francesca F et al (2007) Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 67(13):6092–6099CrossRef
11.
Zurück zum Zitat O’Connell MJ, Krien MJ, Hunter T (2003) Never say never. The NIMA-related protein kinases in mitotic control. Trends Cell Biol 13(5):221–228PubMedCrossRef O’Connell MJ, Krien MJ, Hunter T (2003) Never say never. The NIMA-related protein kinases in mitotic control. Trends Cell Biol 13(5):221–228PubMedCrossRef
12.
Zurück zum Zitat Belham C, Roig J, Caldwell JA et al (2003) A mitotic cascade of NIMA family kinases Nercc1/Nek9 activates the Nek6 and Nek7 kinases. J Biol Chem 278(37):34897–34909PubMedCrossRef Belham C, Roig J, Caldwell JA et al (2003) A mitotic cascade of NIMA family kinases Nercc1/Nek9 activates the Nek6 and Nek7 kinases. J Biol Chem 278(37):34897–34909PubMedCrossRef
13.
Zurück zum Zitat Manning G, Whyte DB, Martinez R et al (2002) The protein kinase complement of the human genome. Science 298(5600):1912–1934PubMedCrossRef Manning G, Whyte DB, Martinez R et al (2002) The protein kinase complement of the human genome. Science 298(5600):1912–1934PubMedCrossRef
14.
Zurück zum Zitat Min Jean Y, Lihua S, David V et al (2003) The serine/threonine kinase Nek6 is required for cell cycle progression through mitosis. J Biol Chem 278(52):52454–52460CrossRef Min Jean Y, Lihua S, David V et al (2003) The serine/threonine kinase Nek6 is required for cell cycle progression through mitosis. J Biol Chem 278(52):52454–52460CrossRef
15.
Zurück zum Zitat O’Regan L, Fry AM (2009) The Nek6 and Nek7 protein kinases are required for robust mitotic spindle formation and cytokinesis. Mol Cell Biol 29(14):3975–3990PubMedCrossRef O’Regan L, Fry AM (2009) The Nek6 and Nek7 protein kinases are required for robust mitotic spindle formation and cytokinesis. Mol Cell Biol 29(14):3975–3990PubMedCrossRef
16.
Zurück zum Zitat Joseph R, Marta N, Aaron G et al (2008) The NIMA-family kinase Nek6 phosphorylates the kinesin Eg5 at a novel site necessary for mitotic spindle formation. Journal of Cell Science 121(pt23):3912–3921 Joseph R, Marta N, Aaron G et al (2008) The NIMA-family kinase Nek6 phosphorylates the kinesin Eg5 at a novel site necessary for mitotic spindle formation. Journal of Cell Science 121(pt23):3912–3921
17.
Zurück zum Zitat Rounak N, Lihua S, Peter F et al (2010) Nek6 mediates human cancer cell transformation and is a potential cancer therapeutic target. Mol Cancer Res 8(5):717–728CrossRef Rounak N, Lihua S, Peter F et al (2010) Nek6 mediates human cancer cell transformation and is a potential cancer therapeutic target. Mol Cancer Res 8(5):717–728CrossRef
18.
Zurück zum Zitat Ahmed S, Thomas G, Ghoussaini M et al (2009) Newly discovered breast cancer susceptibility loci on 3p24 and 17q23. 2. Nat Genet 41(5):585–590PubMedCrossRef Ahmed S, Thomas G, Ghoussaini M et al (2009) Newly discovered breast cancer susceptibility loci on 3p24 and 17q23. 2. Nat Genet 41(5):585–590PubMedCrossRef
19.
Zurück zum Zitat Ke H, John ML, Lee NPY et al (2009) Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer 9:389CrossRef Ke H, John ML, Lee NPY et al (2009) Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer 9:389CrossRef
20.
Zurück zum Zitat Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31:339–346PubMedCrossRef Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31:339–346PubMedCrossRef
21.
22.
Zurück zum Zitat Guillermo C, Ignacio PC, Marcos M (2007) Targeting cell cycle kinases for cancer therapy. Curr Med Chem 14(9):969–985CrossRef Guillermo C, Ignacio PC, Marcos M (2007) Targeting cell cycle kinases for cancer therapy. Curr Med Chem 14(9):969–985CrossRef
23.
Zurück zum Zitat Marcos M, Mariano B (2007) Cell cycle kinases in cancer. Curr Opin Genet Dev 17:60–65CrossRef Marcos M, Mariano B (2007) Cell cycle kinases in cancer. Curr Opin Genet Dev 17:60–65CrossRef
24.
Zurück zum Zitat Chen J, Li L, Zhang Y et al (2006) Interaction of Pin1 with Nek6 and characterization of their expression correlation in Chinese hepatocellular carcinoma patients. Biochem Biophys Res Commun 341(4):1059–1065PubMedCrossRef Chen J, Li L, Zhang Y et al (2006) Interaction of Pin1 with Nek6 and characterization of their expression correlation in Chinese hepatocellular carcinoma patients. Biochem Biophys Res Commun 341(4):1059–1065PubMedCrossRef
25.
Zurück zum Zitat Grigioni WF, D’errico A, Bacci F et al (1989) Primary liver neoplasms: evaluation of proliferative index using MoAb Ki-67. J Pathol 158(1):23–29PubMedCrossRef Grigioni WF, D’errico A, Bacci F et al (1989) Primary liver neoplasms: evaluation of proliferative index using MoAb Ki-67. J Pathol 158(1):23–29PubMedCrossRef
26.
Zurück zum Zitat Ng IO, Na J, Lai EC et al (1995) Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1: a comparison with proliferating cell nuclear antigen. Am J Clin Pathol 104(3):313–318PubMed Ng IO, Na J, Lai EC et al (1995) Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1: a comparison with proliferating cell nuclear antigen. Am J Clin Pathol 104(3):313–318PubMed
27.
Zurück zum Zitat Scholzen T, Gerde J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182(3):311–322PubMedCrossRef Scholzen T, Gerde J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182(3):311–322PubMedCrossRef
28.
Zurück zum Zitat Pang R, Yuen J, Yuen MF et al (2004) PIN1 overexpression and β-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 23(23):4182–4186PubMedCrossRef Pang R, Yuen J, Yuen MF et al (2004) PIN1 overexpression and β-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 23(23):4182–4186PubMedCrossRef
Metadaten
Titel
Clinical and Biological Significance of Never in Mitosis Gene A-Related Kinase 6 (NEK6) Expression in Hepatic Cell Cancer
verfasst von
Xiaolei Cao
Yunfei Xia
Junling Yang
Jinxia Jiang
Li Chen
Runzhou Ni
Liren Li
Zhifeng Gu
Publikationsdatum
01.04.2012
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2012
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-011-9429-0

Weitere Artikel der Ausgabe 2/2012

Pathology & Oncology Research 2/2012 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.